Donate to Remove ads

Got a credit card? use our Credit Card & Finance Calculators

Thanks to Steffers0,Anonymous,CryptoPlankton,GrahamPlatt,Walkeia, for Donating to support the site

GlaxoSmithKline PLC (GSK)

Share latest information on individual companies and hot news discussions. LSE Main Market companies only
Forum rules
No penny shares or promotional posts
idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

GlaxoSmithKline PLC (GSK)

#195174

Postby idpickering » January 21st, 2019, 7:05 am

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman and the Board has started the process to find a successor.


https://www.investegate.co.uk/glaxosmit ... 00466088N/

maximan
2 Lemon pips
Posts: 165
Joined: November 4th, 2016, 3:41 pm
Has thanked: 222 times
Been thanked: 52 times

GSK Completes Acquisition of Tesaro

#195579

Postby maximan » January 22nd, 2019, 2:02 pm

https://www.londonstockexchange.com/exc ... K/13943004.

RNS Number : 7937N
GlaxoSmithKline PLC
22 January 2019




Issued: 22 January 2019, London UK - LSE Announcement



GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company





GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.[url][url][/url][/url]

maximan
2 Lemon pips
Posts: 165
Joined: November 4th, 2016, 3:41 pm
Has thanked: 222 times
Been thanked: 52 times

GlaxoSmithKline Plc (GSK)

#199056

Postby maximan » February 5th, 2019, 1:14 pm

GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
https://www.investegate.co.uk/glaxosmit ... 58321388P/

moorfield
Lemon Quarter
Posts: 1567
Joined: November 7th, 2016, 1:56 pm
Has thanked: 336 times
Been thanked: 372 times

Re: RNS GSK and Merck global alliance

#199068

Postby moorfield » February 5th, 2019, 2:22 pm

More temporary good news for big pharma shareholders.

I wonder how this will work in 52 days time. :o :twisted:

Raptor
Lemon Quarter
Posts: 1619
Joined: November 4th, 2016, 1:39 pm
Has thanked: 139 times
Been thanked: 306 times

Re: GlaxoSmithKline Plc (GSK)

#201878

Postby Raptor » February 17th, 2019, 9:27 am


idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

Re: GlaxoSmithKline Plc (GSK)

#203165

Postby idpickering » February 22nd, 2019, 12:05 pm

GSK response to SFO Statement

In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.


https://www.investegate.co.uk/glaxosmit ... 21488883Q/

idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

Re: GlaxoSmithKline PLC (GSK)

#206368

Postby idpickering » March 8th, 2019, 7:06 am

ViiV positive ph3 data for long acting injectable

ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection


https://www.investegate.co.uk/glaxosmit ... 00022408S/

idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

Re: GlaxoSmithKline PLC (GSK)

#207669

Postby idpickering » March 14th, 2019, 1:28 pm

Is the GSK share price the bargain of the year?

FTSE 100 pharma giant GlaxoSmithKline (LSE: GSK) is heading for a break-up. Chief executive Emma Walmsley will oversee the creation of two companies — a focused and faster-growing pharmaceutical company and a profitable, stable consumer healthcare business.

This strategy isn’t a sure thing, but I think there’s a good chance it will work. Today I’ll explain why. I’ll also take a look a FTSE 250 stock which I think offers an interesting mix of opportunity and risk.

A break-up makes sense


https://www.fool.co.uk/investing/2019/0 ... -the-year/

maximan
2 Lemon pips
Posts: 165
Joined: November 4th, 2016, 3:41 pm
Has thanked: 222 times
Been thanked: 52 times

Glaxo Smith Kline (GSK)

#208706

Postby maximan » March 19th, 2019, 5:50 pm

RNS Number : 3623T
GlaxoSmithKline PLC
19 March 2019




Issued: 19 March 2019, London UK - LSE Announcement



Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer



· GARNET is the single largest study to date of an anti-PD-1 monotherapy in women with advanced or recurrent MSI-H and MSS endometrial cancer

· Results demonstrate clinically meaningful and durable response rates of dostarlimab monotherapy, in MSI-H and MSS tumours

· BLA submission planned for dostarlimab in endometrial cancer at the end of 2019
https://www.investegate.co.uk/glaxosmit ... mab/201903

maximan
2 Lemon pips
Posts: 165
Joined: November 4th, 2016, 3:41 pm
Has thanked: 222 times
Been thanked: 52 times

Re: Glaxo Smith Kline (GSK)

#208709

Postby maximan » March 19th, 2019, 6:01 pm

Sorry link keeps failing. It is on Investigate if you go direct.

Itsallaguess
Lemon Quarter
Posts: 4102
Joined: November 4th, 2016, 1:16 pm
Has thanked: 1477 times
Been thanked: 2589 times

Re: Glaxo Smith Kline (GSK)

#208711

Postby Itsallaguess » March 19th, 2019, 6:10 pm

maximan wrote:
Sorry link keeps failing. It is on Investigate if you go direct.


This one should work -

https://www.investegate.co.uk/glaxosmit ... 45023623T/

Cheers,

Itsallaguess

maximan
2 Lemon pips
Posts: 165
Joined: November 4th, 2016, 3:41 pm
Has thanked: 222 times
Been thanked: 52 times

Re: GlaxoSmithKline PLC (GSK)

#209173

Postby maximan » March 21st, 2019, 4:47 pm

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate. These results, published in Blood Cancer Journal (link) build upon results from the pre-specified interim analysis, which were first presented at the American Society of Haematology Congress in 2017.

https://www.investegate.co.uk/glaxosmit ... 00016374T/

idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

Re: GlaxoSmithKline PLC (GSK)

#213783

Postby idpickering » April 9th, 2019, 7:05 am

FDA approves ViiV's two-drug HIV regimen, Dovato

ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen.1


https://www.investegate.co.uk/glaxosmit ... 00025072V/

idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

Re: GlaxoSmithKline PLC (GSK)

#227643

Postby idpickering » June 7th, 2019, 7:05 am

FDA approval for Nucala self-administration

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector.


https://www.investegate.co.uk/glaxosmit ... 00024560B/

idpickering
Lemon Quarter
Posts: 4696
Joined: November 4th, 2016, 5:04 pm
Has thanked: 680 times
Been thanked: 1526 times

Re: GlaxoSmithKline PLC (GSK)

#235421

Postby idpickering » July 10th, 2019, 7:18 am

ViiV switch study shows 2DR as effective as 3DR

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen


https://www.investegate.co.uk/glaxosmit ... 00030093F/

daveh
Lemon Slice
Posts: 625
Joined: November 4th, 2016, 11:06 am
Has thanked: 47 times
Been thanked: 191 times

Re: GlaxoSmithKline PLC (GSK)

#235525

Postby daveh » July 10th, 2019, 12:28 pm

idpickering wrote:ViiV switch study shows 2DR as effective as 3DR

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen


https://www.investegate.co.uk/glaxosmit ... 00030093F/


My question is why would you want to move from 3DR to 2DR regime. Maybe less complicated to take as the two drugs are combined in a single pill (its unclear whether the 3DR regime is a single pill or 3 pills). Possibility of fewer side effects on the 2DR regime. I looked through the RNS to see if there was a reason given why the 2DR regime might be advantageous, but it didn't seem to say. If I have time I'll do a bit of research and see if I can see what advantages there are to the 2DR regime.

tjh290633
Lemon Quarter
Posts: 3786
Joined: November 4th, 2016, 11:20 am
Has thanked: 254 times
Been thanked: 1297 times

Re: GlaxoSmithKline PLC (GSK)

#237147

Postby tjh290633 » July 16th, 2019, 11:01 pm

My broker has sent me a notice of Corporate Action today, regarding the splitting off of the new Joint Venture with Pfizer.

Other than the vote having been passed at the AGM approving this, I have seen nothing else. No RNS of recent date. I have had a look on the GSK website and see nothing there. Have I missed something, or is this in anticipation of an announcement with the Q1 results next week?

TJH

PinkDalek
Lemon Quarter
Posts: 4500
Joined: November 4th, 2016, 1:12 pm
Has thanked: 1049 times
Been thanked: 1201 times

Re: GlaxoSmithKline PLC (GSK)

#237154

Postby PinkDalek » July 16th, 2019, 11:54 pm

tjh290633 wrote:My broker has sent me a notice of Corporate Action today, regarding the splitting off of the new Joint Venture with Pfizer.

Other than the vote having been passed at the AGM approving this, I have seen nothing else. No RNS of recent date. I have had a look on the GSK website and see nothing there. Have I missed something, or is this in anticipation of an announcement with the Q1 results next week?

TJH


Other than the AGM, the only RNS of detail I recall concerning this is below:

https://www.investegate.co.uk/glaxosmit ... 00039434K/

I can't say I've kept a close eye on this and I'd assumed the listing was some years away in view of the Within 3 years of the closing of the transaction, GSK intends to separate the Joint Venture via a demerger of its equity interest and a listing of GSK Consumer Healthcare on the UK equity market.

Did you broker provide any further background?

daveh
Lemon Slice
Posts: 625
Joined: November 4th, 2016, 11:06 am
Has thanked: 47 times
Been thanked: 191 times

Re: GlaxoSmithKline PLC (GSK)

#237191

Postby daveh » July 17th, 2019, 9:08 am

As I posted else where where all that my broker said was:
Demerger.

Share holders will recieve Consumer Healthcare Joint Venture (CHJV) shares, at a rate to be determined for each Existing GlaxoSmithKline PLC (GSK) share held on the Ex-entitlement Date, which is yet to be determined.
Important Information & Other Key Dates:
On 19th December 2018, GSK and Pfizer entered into an agreement under which, upon closing of the proposed transaction, Pfizer will contribute its consumer healthcare business to GSK's existing consumer healthcare business in return for equity shares in this business. As a result, a newly Demerged Consumer Health Joint Venture will be created in which GSK will have a controlling 68 percent equity interest and Pfizer 32 percent equity interest.

The Demerger received shareholder approval at the General Meeting held on 8th May 2019.



So no real detail at all and like PD I wasn't expecting anything to happen soon if at all.

tjh290633
Lemon Quarter
Posts: 3786
Joined: November 4th, 2016, 11:20 am
Has thanked: 254 times
Been thanked: 1297 times

Re: GlaxoSmithKline PLC (GSK)

#237196

Postby tjh290633 » July 17th, 2019, 9:17 am

That is virtually word for word what my broker (Halifax badged as Lloyds) said.

It may be that the penny has just dropped that they have not mentioned it earlier. Alternatively someone gave them a heads up that the due date had been decided and will be announced.

TJH


Return to “Company Share news (LSE Main Market)”

Who is online

Users browsing this forum: No registered users and 8 guests